Sanofi Pasteur, A Sanofi Company

This Phase 2 study tests a new yellow fever vaccine (vYF) against the current licensed vaccine (Stamaril) in 690 healthy adults aged 18-60 in Europe and Asia. Participants receive one shot, and researchers measure immune response and safety over 5 years. The goal is to see if the…

This study tests a new vaccine (PCV21) that protects against 21 types of pneumonia-causing bacteria. About 1,700 healthy infants will receive either the new vaccine or an existing one alongside their routine shots. The goal is to see if the new vaccine is safe and helps babies bu…

This study tests a new pentavalent meningococcal vaccine (MenPenta) that aims to protect against five types of meningococcal bacteria (A, B, C, W, Y) in healthy children, toddlers, and infants. Researchers will compare it to existing licensed vaccines and check how well it works …

This study tests a new mRNA vaccine designed to protect adults aged 60 and older from two viruses that can cause serious lung infections: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). About 1,530 participants will receive either the vaccine or a placebo to c…

This study tests a new 21-valent pneumococcal vaccine (PCV21) in healthy infants, toddlers, children, and adolescents who need catch-up vaccination. Around 1,268 participants will receive either PCV21 or the current 20-valent vaccine. Researchers will monitor side effects and mea…

This study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatments or vaccines a…